Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2018, Article ID 9462475, 11 pages
https://doi.org/10.1155/2018/9462475
Research Article

A Seven-Year Retrospective Study on the Surveillance of Hepatitis B in Laos

1Centre d’Infectiologie Lao-Christophe Mérieux, Vientiane, Laos
2IRD, UPS, UMR 152 PHARMADEV, Université de Toulouse, Toulouse, France
3Fondation Mérieux, Lyon, France
4Hôpitaux Universitaires Paris Seine Saint Denis, Université Paris 13, Sorbonne Paris Cité, Paris, France
5INSERM U1052, CNRS UMR 5286, Cancer Research Center of Lyon, Lyon, France
6Institut Pasteur, Organisation Nucléaire et Oncogenèse, Paris, France

Correspondence should be addressed to Phimpha Paboriboune; gro.soal-mcc@ahpmihp

Received 3 October 2017; Revised 1 February 2018; Accepted 18 February 2018; Published 1 April 2018

Academic Editor: Piero Luigi Almasio

Copyright © 2018 Phimpha Paboriboune et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Zampino, A. Boemio, C. Sagnelli et al., “Hepatitis B virus burden in developing countries,” World Journal of Gastroenterology, vol. 21, no. 42, pp. 11941–11953, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. Centers for Disease Control and Prevention (CDC), “Hepatitis B vaccine birthdose practices in a country where hepatitis B is endemic - Laos,” Morbidity and Mortality Weekly Report (MMWR), vol. 62, pp. 587–590, 2013. View at Google Scholar
  3. A. P. Black, P. Nouanthong, N. Nanthavong et al., “Hepatitis B virus in the Lao People's Democratic Republic: a cross sectional serosurvey in different cohorts,” BMC Infectious Diseases, vol. 14, article 457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. N. H. Y. Kong and P. K. H. Chow, “Conducting randomised controlled trials across countries with disparate levels of socio-economic development: The experience of the Asia-Pacific Hepatocellular Carcinoma Trials Group,” Contemporary Clinical Trials, vol. 36, no. 2, pp. 682–686, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. Globocan 2012 - Home. Available from: http://globocan.iarc.fr/Default.aspx.
  6. J. M. Llovet, A. Villanueva, A. Lachenmayer, and R. S. Finn, “Advances in targeted therapies for hepatocellular carcinoma in the genomic era,” Nature Reviews Clinical Oncology, vol. 12, no. 7, pp. 408–424, 2015. View at Publisher · View at Google Scholar
  7. S. K. Sarin, M. Kumar, G. K. Lau et al., “Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update,” Hepatology International, vol. 10, no. 1, pp. 1–98, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. N. A. Terrault, N. H. Bzowej, K.-M. Chang, J. P. Hwang, M. M. Jonas, and M. H. Murad, “AASLD guidelines for treatment of chronic hepatitis B,” Hepatology, vol. 63, no. 1, pp. 261–283, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. Laos GDP per capita | 1984–2016 | Data | Chart | Calendar | Forecast | News. Available from: http://www.tradingeconomics.com/laos/gdp-per-capita.
  10. B. S. Blumberg, “Sex differences in response to hepatitis b virus,” Arthritis & Rheumatism, vol. 22, no. 11, pp. 1261–1266, 1979. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, 2014. View at Publisher · View at Google Scholar
  12. J. W. Park, M. Chen, M. Colombo et al., “Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study,” Liver International, vol. 35, no. 9, pp. 2155–2166, 2015. View at Publisher · View at Google Scholar
  13. R. X. Zhu, W.-K. Seto, C.-L. Lai, and M.-F. Yuen, “Epidemiology of hepatocellular carcinoma in the Asia-Pacific region,” Gut and Liver, vol. 10, no. 3, pp. 332–339, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Bertani, P. Pineau, S. Loli et al., “An Atypical Age-Specific Pattern of Hepatocellular Carcinoma in Peru: A Threat for Andean Populations,” PLoS ONE, vol. 8, no. 6, Article ID e67756, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Marchio, S. Bertani, T. Rojas Rojas et al., “A peculiar mutation spectrum emerging from young peruvian patients with hepatocellular carcinoma,” PLoS ONE, vol. 9, no. 12, Article ID e114912, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Ruiz, T. Rojas Rojas, F. Berrospi et al., “Hepatocellular carcinoma surgery outcomes in the developing world: A 20-year retrospective cohort study at the National Cancer Institute of Peru,” Heliyon, vol. 2, no. 1, Article ID e00052, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. J. D. Yang, A. Gyedu, M. Y. Afihene et al., “Hepatocellular carcinoma occurs at an earlier age in Africans, particularly in association with chronic Hepatitis B,” American Journal of Gastroenterology, vol. 110, no. 11, pp. 1629–1631, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. X. Chen, F. Wu, Y. Liu et al., “The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: Evidence from two meta-analyses,” Oncotarget , vol. 7, no. 31, pp. 49299–49309, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. J.-M. Pawlotsky, G. Dusheiko, A. Hatzakis et al., “Virologic Monitoring of Hepatitis B Virus Therapy in Clinical Trials and Practice: Recommendations for a Standardized Approach,” Gastroenterology, vol. 134, no. 2, pp. 405–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. C.-J. Chen, H.-I. Yang, and U. H. Iloeje, “Hepatitis B virus DNA levels and outcomes in chronic hepatitis B,” Hepatology, vol. 49, no. 5, pp. S72–S84, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. H. You, Y. Kong, J. Hou et al., “Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B,” Scientific Reports, vol. 6, Article ID 37498, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Zhang, C.-Y. Wang, Y.-X. Li, Y. Pan, J.-Q. Niu, and S.-M. He, “Determination of the upper cut-off values of serum alanine aminotransferase and aspartate aminotransferase in Chinese,” World Journal of Gastroenterology, vol. 21, no. 8, pp. 2419–2424, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Marcellin, T.-T. Chang, S. G. Lim et al., “Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B,” The New England Journal of Medicine, vol. 348, no. 9, pp. 808–816, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Marcellin, E. Gane, M. Buti et al., “Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study,” The Lancet, vol. 381, no. 9865, pp. 468–475, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. C.-Y. Wu, J.-T. Lin, H. J. Ho et al., “Association of nucleos(T)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B - A nationwide cohort study,” Gastroenterology, vol. 147, no. 1, pp. 143–e5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. E. De Clercq and G. Li, “Approved antiviral drugs over the past 50 years,” Clinical Microbiology Reviews, vol. 29, no. 3, pp. 695–747, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. WHO | WHO Model Lists of Essential Medicines. Available from: http://www.who.int/medicines/publications/essentialmedicines/). View at Publisher · View at Google Scholar
  28. F. Suzuki, Y. Suzuki, A. Tsubota et al., “Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy,” Journal of Hepatology, vol. 37, no. 6, pp. 824–830, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Papatheodoridis, I. Vlachogiannakos, E. Cholongitas et al., “Discontinuation of oral antivirals in chronic hepatitis B: A systematic review,” Hepatology, vol. 63, no. 5, pp. 1481–1492, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Izzo, M. Piccirillo, V. Albino et al., “Prospective screening increases the detection of potentially curable hepatocellular carcinoma: Results in 8900 high-risk patients,” HPB, vol. 15, no. 12, pp. 985–990, 2013. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Fusco, P. Piselli, S. Virdone et al., “Infection with hepatitis viruses, FIB-4 index and risk of hepatocellular carcinoma in southern Italy: a population-based cohort study,” Infectious Agents and Cancer, vol. 11, no. 1, pp. 1–8, 2016. View at Publisher · View at Google Scholar · View at Scopus